While chemotherapy, radiotherapy, and surgery have long been considered the basis of cancer treatment, the first successful FDA-approved ICB drug in 2011—the anti-CTLA-4 monoclonal antibody ipilimumab [15]—revolutionized immunotherapy as a new pillar of cancer therapy. Here, CTLA4 is linked to cancer.